GFT505 80mg
GFT505 80mg is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity
Clinical Trials (5)
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5